李唯实 Weishi Li

June 18, 2019, Covington Alert

On June 10, 2019, the State Council (China’s chief executive agency) promulgated the long-awaited Regulation on the Administration of Human Genetic Resources (the “Regulation”), which will become effective on July 1, 2019.  The Regulation supersedes the currently effective regulations and guidance on human genetic resources (“HGR”).  

April 8, 2019, Covington Alert

On March 15, 2019, China’s National People’s Congress voted to adopt a new Foreign Investment Law (the “FIL”).  The FIL will come into effect on January 1, 2020 and may significantly change China’s framework for regulating foreign investment.  Foreign invested entities (“FIEs”) established prior to the FIL’s effective date will have five years to amend their ...

March 27, 2018, Covington Alert

China has reorganized many of the ministries and commissions under its chief executive body, the State Council, creating a new super-ministry to replace the China Food and Drug Administration (“CFDA”) and other healthcare agencies.

November 6, 2017, Covington Alert

China has recently announced several initiatives to reform its regulation of drugs and medical devices that could have a significant impact on pharmaceutical and medical device companies doing business in China.

May 23, 2017, Covington Alert

On May 11 and 12, 2017, the China Food and Drug Administration (“CFDA”) published drafts of four proposed policies in the form of circulars (or notices) for public comment. These “Proposed Policies” include significant reforms in the areas of the new drug and device approval process (“Circular 52”), clinical trial regulation (“Circular 53”), life-cycle ...

January 23, 2017, Covington Alert

On January 9, 2017, eight Chinese ministries announced a significant new policy that aims to reduce marked-up prices and corruption in multi-tier distribution chains. The policy effectively requires that under most circumstances, at most two invoices may be issued throughout the distribution chain, with one from the manufacturer to a distributor and another from ...

December 21, 2016

SHANGHAI—China Business Law Journal has named Covington partner Weishi Li to its “A-List” of the top 100 private practice lawyers in China. Ms. Li is one of two life sciences lawyers recognized by the magazine. China Business Law Journal’s inaugural A-list is based on interviews of in-house counsel in China and around the world, as well as partners at Chinese ...

September 21, 2016

June 3, 2015, LegalStudio

January 9, 2013

华盛顿特区，2013年1月9日—科文顿•柏灵律师事务所已开设上海代表处，这是该所分别于2008年在北京和2012年末在首尔设立两家代表处之后，在亚洲开设的第三家代表处。 科文顿的这三家代表处目前共有20位律师，这使该所被AmLaw评为拥有亚洲办事处的50家顶级律师事务所之一。这一举措增强了科文顿在公司法、争议解决、调查、监管等方面为寻求在亚洲开展业务的欧美客户及希望在世界其他地区开展业务的亚洲客户提供服务的能力。 科文顿律师事务所管理委员会主席Timothy Hester表示，“上海办事处的设立增强了本所在华开展生命科学、技术交易、反海外腐败法、资本市场、并购及证券等领域的业务能力，并使我们能在亚洲最具活力的经济中心的核心地区提供这些服务。” ...

September 5, 2012

WASHINGTON, DC, September 5, 2012 — Covington & Burling is pleased to announce the addition of Weishi Li as a partner to its corporate team, further bolstering the firm’s global transactional and IP capabilities in the life sciences and technology sectors. Ms. Li will be based in Shanghai when that office opens. Ms. Li’s practice covers a wide range of ...